Skip to content
orbyd

Dossier · CCRN · Dormant

CCRN · Cross Country Healthcare, Inc. · Stock research

LOW Earnings inflection Catalyst · m-and-a-special-situations managed-care-health-services

Last analysed ·

Current thesis

Deal-pinned cash merger-arb, not a momentum trade. Knox Lane taking CCRN private at $13.25 cash; HSR cleared 2026-06-22 for both the merger and the locums sale, leaving only the 2026-07-16 shareholder vote. ~0.3% capped upside vs ~25% deal-break downside fails the >3:1 bar dormant for a momentum book.

Invalidation trigger

A daily close below $12.50 breaks the ~$13.20 arb band and signals deal doubt; a merger-termination 8-K or a failed 2026-07-16 shareholder vote would gap the stock toward standalone ~$9–10. Inverse: vote passes, deal closes near $13.25 and delists, leaving zero further upside.

Thesis status

Open commitment catalyst 3d agoscored if the trigger above fires How this is scored →

Latest analysis and events for CCRN —

As of 2026-07-11, orbyd's latest analysis for Cross Country Healthcare, Inc. (CCRN): Deal-pinned cash merger-arb, not a momentum trade. Knox Lane taking CCRN private at $13.25 cash; HSR cleared 2026-06-22 for both the merger and the locums sale, leaving only the 2026-07-16 shareholder vote. ~0.3% capped upside vs ~25% deal-break downside fails the >3:1 bar dormant for a momentum book.

Invalidation trigger: A daily close below $12.50 breaks the ~$13.20 arb band and signals deal doubt; a merger-termination 8-K or a failed 2026-07-16 shareholder vote would gap the stock toward standalone ~$9–10. Inverse: vote passes, deal closes near $13.25 and delists, leaving zero further upside.

Most recent dated event on file: — catalyst 3d ago.

Current Thesis

CCRN is a deal-pinned cash merger-arb in its final innings, not a narrative-momentum name, and belongs in the dormant/avoid bucket for a trend book. On 2026-05-06 Knox Lane a private-equity sponsor buying through KL Criss Cross Intermediate, LLC agreed to take the company private at $13.25/share cash, ~$437M, a 31% premium to the prior close and ~45% to the 90-day VWAP. The prior near-term binary has now cleared: the HSR waiting periods for both the merger and the carve-out of the locums business to All Star Healthcare Solutions expired at 11:59 p.m. ET on 2026-06-22 with no second request. The remaining gate is the 2026-07-16 12:00 p.m. ET shareholder vote (virtual; board unanimously "FOR"). The stock last referenced $13.21 (2026-06-30) against $13.25 terms a ~$0.04 / ~0.3% gross spread. The tape is bond-like: no pullback to buy, no breakout to chase, upside mathematically capped at $13.25.

Bullish and bearish views on Cross Country Healthcare, Inc.

The model's bull view on Cross Country Healthcare, Inc. (CCRN), in brief: The antitrust risk that killed the last deal is now retired: HSR cleared cleanly on 2026-06-22 for both the merger and the locums sale. The bear view: Payoff structure inverts the mandate: best case is ~$0.04 (~0.3%) to $13.25; a break sends the stock toward standalone ~$9–10 (the pre-announcement reference was ~$10.11–$10.23 on 2026-05-02), a ~25%+ drop. Both cases follow in full.

Bull Case

  • The antitrust risk that killed the last deal is now retired: HSR cleared cleanly on 2026-06-22 for both the merger and the locums sale. Unlike the terminated Aya Healthcare deal ($18.61/share, $615M, announced Dec-2024, terminated 2025-12-03 on a stalled horizontal-overlap review during a 43-day government shutdown; Aya paid a $20M break fee), Knox Lane is a financial sponsor with no staffing overlap no FTC theory to pursue.
  • Only two low-probability variables remain: the 2026-07-16 vote (board unanimous, PE cash at a 31% premium — passage is the base case) and customary closing conditions. With HSR done, the deal is guided to close in Q3-2026, likely within days-to-weeks of the vote.
  • Spread implies near-certain completion: $13.21 vs $13.25 ≈ 0.3% gross; against a close weeks away, that is roughly a 3–6% annualized clip the market pricing very high deal confidence.
  • Sponsor is bonded to close: a $14,213,075 Parent regulatory termination fee is payable if antitrust conditions fail or Knox Lane breaches its regulatory obligations, and the locums sale to All Star was sequenced through the same HSR window rather than left as a trailing condition.

Bear Case

  • Payoff structure inverts the mandate: best case is ~$0.04 (~0.3%) to $13.25; a break sends the stock toward standalone ~$9–10 (the pre-announcement reference was ~$10.11–$10.23 on 2026-05-02), a ~25%+ drop. Risking ~25% to make ~0.3% is the opposite of a >3:1 setup.
  • The standalone business is contracting into the buyout: Q1-2026 (reported 2026-05-07) revenue $241.1M, -17.8% YoY (vs $293.4M); net loss $4.3M / -$0.14 LPS (vs -$0.02 a year prior); Nurse & Allied ($201.4M) and Physician ($39.6M) both showed lower volumes and margin compression. A deal break leaves no fundamental floor and the re-rate could undershoot $10.
  • Merger-objection litigation is live: two stockholder suits plus demand letters allege proxy-disclosure deficiencies; the company denies them and has filed supplemental disclosures (DEFA14A). These rarely block a deal but can generate headline noise into the vote.
  • Second take-private attempt in ~18 months: management already had one buyout collapse on regulatory timing, so the tape stays headline-sensitive even with Knox Lane's cleaner profile.

Setup & Price Structure

Price sits pinned at $13.21 (2026-06-30), ~0.3% below the $13.25 cash terms and inside a 52-week range of $7.43–$14.88 the high set on takeover optimism, the low on the standalone staffing downcycle. There is no trend to trade: volatility has collapsed to the arb band as the deal de-risked through HSR clearance. The only structurally meaningful level is ~$9–10, the ungapped standalone zone the stock would seek if the deal broke. A drift under $12.50 would be the first tape signal that arb desks are pricing rising completion risk. For a momentum book there is no entry here the move to terms is spent and the remaining reward is a rounding error.

Catalyst Calendar (next 30 days)

  • ~early-Aug 2026 (est.) Q2-2026 print would ordinarily land here, but a Q3 close likely pre-empts any earnings call; treat as unlikely to trade.

Elapsed catalysts

  • 2026-07-16, 12:00 p.m. ET special shareholder meeting to vote on the merger; board recommends "FOR". The decisive remaining gate. _(passed 3d ago)_
  • ~2026-07-17 to end of Q3 expected deal closing and NASDAQ delisting once the vote passes and customary conditions are met; could follow the vote by days. _(passed 2d ago)_
  • HSR gate (2026-06-22) has elapsed and cleared no longer a forward catalyst. _(passed 27d ago)_

What Would Change Our Mind

The dormant read flips only on a deal-break sequence: an 8-K announcing merger termination, a failed or postponed 2026-07-16 vote, or a financing/MAC dispute surfacing before close. Any of those would sever the $13.25 anchor and re-expose the declining standalone staffing business, gapping the stock toward ~$9–10 and only then, and only if the travel-nurse staffing cycle simultaneously re-accelerated creating a possible momentum setup. That requires two independent events (deal break AND cycle turn), which is why the name stays parked. On the inverse, a clean vote and Q3 close simply removes the ticker via delisting with no further upside.

Correlation Notes

Once inside the arb band, CCRN trades on deal-completion odds, not on healthcare-staffing beta or the broad tape its correlation to SPY, and staffing peers (AMN, HSTM) has decayed toward zero. The live risk factors are idiosyncratic and legal/regulatory: HSR (now cleared), the shareholder vote, and merger litigation. A deal break would instantly re-couple CCRN to the travel-nurse staffing cycle, where bill-rate normalization and lower hospital demand have driven the -17.8% YoY revenue decline. Until then the name behaves like a short-dated bond maturing at $13.25.

Notes

  • NOT managed care CCRN is healthcare/travel-nurse STAFFING; prior 'health-managed-care' theme tag is mislabeled.
  • Aya Healthcare's $18.61/share ($615M) deal TERMINATED 2025-12-03 on FTC antitrust (horizontal overlap); Aya paid $20M break fee.
  • Knox Lane buyout: $13.25/share cash, ~$437M, announced 2026-05-06, entity KL Criss Cross Intermediate LLC; expected Q3-2026 close; reciprocal termination fee ~$14.2M.
  • Knox Lane is a PE sponsor with no staffing overlap → low antitrust risk; this is why the spread is tight (~1%) and the market prices high completion odds.
  • HSR waiting period expires ~2026-06-22 absent second request; shareholder special meeting date to be set in definitive DEFM14A (PREM14A filed late-May 2026).
  • Q1 2026: revenue $241.1M (-17.8% YoY), net loss $4.3M, LPS -$0.14 (reported early-May 2026) standalone business declining; no fundamental floor if deal breaks.
  • Pinned merger-arb, not a momentum name. Keep DORMANT/pass unless deal breaks AND staffing cycle re-accelerates two independent events.
  • Upside capped at $13.25 (then delist); deal-break downside ~$9-10. R/R is ~1% up vs ~25-30% down fails the >3:1 rule.
  • NOT managed care CCRN is healthcare/travel-nurse STAFFING; legacy 'health-managed-care' theme tag is mislabeled.
  • Knox Lane buyout: $13.25/share cash, ~$437M, ~17x EBITDA, announced 2026-05-06, acquiring entity KL Criss Cross Intermediate, LLC; guided Q3-2026 close. 31.06% premium to 2026-05-06 close, ~45% to 90-day VWAP.
  • Outside date 2026-10-06, with up to two automatic 3-month extensions to 2027-01-06 and 2027-04-06 if only HSR clearance is outstanding.
  • HSR waiting period expires 2026-06-22 absent a second request the key near-term binary. Parent regulatory termination fee $14,213,075.
  • Prior Aya Healthcare deal ($18.61/share, $615M, announced Dec-2024) terminated 2025-12-03 HSR clearance could not complete (43-day government shutdown stalled review of the horizontally-overlapping combination); Aya paid $20M break fee. Knox Lane (PE, no staffing overlap) has no horizontal-overlap theory, hence the thin spread.
  • Q1-2026 (reported 2026-05-07): revenue $241.1M (-17.8% YoY), net loss $4.3M, LPS -$0.14 standalone business declining; no fundamental floor if deal breaks (~$9–10 standalone vs $13.25 terms).
  • Merger closing references a related 'Locums Transaction' (physician staffing); terms not fully detailed in preliminary proxy track before the vote.
  • Definitive proxy (DEFM14A) / special-meeting date still TBD as of early-June 2026; virtual meeting at virtualshareholdermeeting.com/CCRN2026SM.
  • Pinned merger-arb: upside ~0.5% capped at $13.25 (then delist), deal-break downside ~22%. Fails >3:1 R/R. Keep DORMANT/pass unless deal breaks AND staffing cycle re-accelerates two independent events.
  • Earnings blackout reminder: Q2-2026 print ~early-August (outside any near-term window).
  • NOT managed care CCRN is healthcare/travel-nurse + locum-tenens STAFFING; any 'health-managed-care' theme tag is mislabeled and should be corrected.
  • Pinned cash merger-arb, not a momentum name. Keep dormant unless the deal BREAKS and the staffing cycle re-accelerates two independent events.
  • Knox Lane buyout: $13.25/share cash, ~$437M, ~17x EBITDA, announced 2026-05-06, acquirer KL Criss Cross Intermediate, LLC; 31.06% premium / ~45% to 90-day VWAP.
  • REFRESH 2026-06-21: definitive proxy (DEFM14A) now filed; shareholder special meeting set 2026-07-16 (virtual), board unanimously 'FOR'.
  • HSR waiting period for BOTH the merger and the related Locums Transaction expires 2026-06-22 at 11:59 p.m. absent a second request the near-term binary.
  • Outside date 2026-10-06 with up to two automatic 3-month extensions (2027-01-06, 2027-04-06) if only HSR clearance remains outstanding. Parent regulatory termination fee $14,213,075.
  • Prior Aya Healthcare deal ($18.61/share, $615M, announced Dec-2024) terminated 2025-12-03 on HSR timing (43-day government shutdown); Aya paid $20M break fee. Knox Lane's PE profile has no horizontal overlap → cleaner antitrust path.
  • Q1-2026 (reported 2026-05-07): revenue $241.1M (-17.8% YoY), net loss $4.3M, -$0.14 LPS. Standalone declining; deal-break downside ~$9–10 (pre-announce ~$10.11–$10.23 on 2026-05-02).
  • Upside capped ~0.5% to $13.25 — then Nasdaq delist; deal-break downside ~22–24%. R/R fails the >3:1 rule earnings-blackout/binary-catalyst name, no momentum edge while pinned.
  • NOT managed care CCRN is healthcare/travel-nurse STAFFING; any 'health-managed-care' theme tag is mislabeled.
  • Knox Lane buyout: $13.25/share cash, ~$437M, ~17x EBITDA, announced 2026-05-06 via KL Criss Cross Intermediate, LLC; 31% premium to close, ~45% to 90-day VWAP; guided Q3-2026 close.
  • HSR waiting periods for BOTH the merger and the locums sale to All Star Healthcare Solutions expired cleanly at 11:59 p.m. ET on 2026-06-22 with no second request the prior near-term binary is CLEARED.
  • Remaining gate is the 2026-07-16 12:00 p.m. ET shareholder special meeting (virtual; board unanimous FOR) plus customary conditions; delisting follows close.
  • Two stockholder suits + demand letters allege proxy-disclosure deficiencies; company denies and filed supplemental DEFA14A disclosures routine merger-objection litigation, low block risk.
  • Parent regulatory termination fee $14,213,075; outside date 2026-10-06 (HSR-contingent extensions now moot since HSR cleared).
  • Prior Aya Healthcare deal ($18.61/share, $615M, announced Dec-2024) terminated 2025-12-03 on stalled HSR review during a 43-day government shutdown; Aya paid $20M break fee.
  • Q1-2026 (reported 2026-05-07): revenue $241.1M -17.8% YoY, net loss $4.3M, -$0.14 LPS standalone business declining; no fundamental floor if deal breaks (~$9–10 standalone reference).
  • R/R ~0.3% up vs ~25% down fails >3:1. Keep dormant/pass unless deal breaks AND staffing cycle re-accelerates two independent events.
  • Earnings blackout / merger noise: Q2-2026 print (~early Aug) likely pre-empted by a Q3 close; unlikely to trade.

Related · shared themes

MRCY

Mercury Systems Inc

Defense-electronics turnaround re-rating inside an accelerating modernization tape: Q3 FY26 (2026-05-06) printed record bookings $348M (+73.7% YoY), 1.48 book-to-bill, record ~$1.6B backlog and +46% EBITDA, with FCF guided positive. But the stock just reversed ~16% off its $128.45 ATH; the ~2026-08-10 Q4/full-year print is the next binary.

MEDIUM

OSCR

Oscar Health, Inc.

Margin-recovery re-rate has carried the ACA pure-play leader to new highs, clearing the $30.38 prior 52-wk high on the +11% July 1 break with managed-care breadth (CNC/MOH/AGL) accelerating. But at $30.54 it trades ~28% above the $23.8 consensus target into the Aug 6 Q2 binary a late-leg continuation, not a pre-consensus entry.

MEDIUM

SIMO

Silicon Motion Technology Corporation

NAND-controller toll-booth on the steepest flash shortage in ~15 years: TrendForce H1 2026 contract +>100% cumulative, H2 still rising with no capacity adds. Q1 record +105% YoY, sell-side chasing to $400/$450. Fundamental leg ACCELERATING, but the tape is digesting a 4x into insider selling the 2026-07-29 Q2 print is the next binary.

MEDIUM

XPO

XPO, Inc.

Freight-cycle upturn is the accelerating narrative: LTL volume and contract pricing re-accelerating after a multi-year trucking recession, with SAIA May tonnage +8.4% confirming the cluster. XPO layers operating-ratio self-help (Q1 LTL OR 83.9%, -200bps YoY) on top. The 2026-07-30 Q2 print is the binary that validates or breaks the "comfortably ahead" yield guide.

MEDIUM

See also · stocks to watch

managed care and health-services stocks to watch